Use of Antihyperglycemic Drugs and Risk of Cancer in Patients with Diabetes

被引:16
作者
Sondergaard, Christian Sümeghy [1 ]
Esquivel, Paulina Nunez [1 ]
Dalamaga, Maria [2 ]
Magkos, Faidon [1 ]
机构
[1] Univ Copenhagen, Fac Sci, Dept Nutr Exercise & Sports, Rolighedsvej 26, DK-1958 Frederiksberg, Copenhagen, Denmark
[2] Natl & Kapodistrian Univ, Athens Med Sch, Dept Biol Chem, Athens, Greece
关键词
Antidiabetic medication; Hyperglycemia; Diabetes therapy; Tumor; Cancer risk; PEPTIDE-1 RECEPTOR AGONISTS; POPULATION-BASED COHORT; COLORECTAL-CANCER; INSULIN ANALOGS; ANTIDIABETIC THERAPY; GASTRIC-CANCER; BREAST-CANCER; DOUBLE-BLIND; LUNG-CANCER; METFORMIN;
D O I
10.1007/s11912-022-01344-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of Review Diabetes is associated with an increased risk for several types of cancer. Therefore, use of antihyperglycemic medications to lower blood glucose may modify cancer risk. Here we review available data on the link between the most common classes of antihyperglycemic agents and cancer risk among patients with diabetes. Recent Findings A database search was conducted between February 2022 and June 2022 on PubMed and Embase for systematic reviews and meta-analyses investigating the association between antihyperglycemic agents and risk of cancer. Use of biguanides such as metformin is associated with 20-30% lower risk for all cancer incidence, and somewhat greater benefit for cancer-related mortality. Alpha-glucosidase inhibitors, e.g., acarbose, have not been consistently associated with cancer. Similarly, no consistent effects have been reported for thiazolidinediones, but the relationship with cancer seems to depend on the type of drug, dose, and duration of treatment. Exposure to various types of incretin-based therapies (glucagon-like peptide-1 agonists and dipeptidyl peptidase-4 inhibitors) has not been found to significantly modify cancer risk. Inhibitors of sodium glucose cotransporter-2 may raise risk for bladder cancer and reduce risk for gastrointestinal cancer. Use of insulin and insulin analogs is associated with a significant increase in total cancer risk by almost 50% compared to other antihyperglycemic drugs. Likewise, insulin secretagogues like sulfonylureas have generally been linked to greater risk for cancer by similar to 20%, although these associations may be agent-specific and dose-dependent. Current evidence suggests that the risk of cancer associated with the use of antihyperglycemic medications among patients with diabetes depends on the class of drug and type of agent, dosage, and duration of treatment. More research is needed to delineate the mechanisms by which these agents affect the process of carcinogenesis.
引用
收藏
页码:29 / 40
页数:12
相关论文
共 109 条
  • [1] Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials
    Abd El Aziz, Mirna
    Cahyadi, Oscar
    Meier, Juris J.
    Schmidt, Wolfgang E.
    Nauck, Michael A.
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (04) : 699 - 704
  • [2] Diabetes, metformin and cancer risk in myotonic dystrophy type I
    Alsaggaf, Rotana
    Pfeiffer, Ruth M.
    Wang, Youjin
    St George, Diane Marie M.
    Zhan, Min
    Wagner, Kathryn R.
    Amr, Sania
    Greene, Mark H.
    Gadalla, Shahinaz M.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (03) : 785 - 792
  • [3] [Anonymous], 1985, WHO TECH REP SER, P1
  • [4] [Anonymous], 2013, JPN PHARMACOL THER
  • [5] Mechanisms of obesity-induced metabolic and vascular dysfunctions
    Atawia, Reem T.
    Bunch, Katharine L.
    Toque, Haroldo A.
    Caldwell, Ruth B.
    Caldwell, Robert W.
    [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2019, 24 : 890 - 934
  • [6] Baron Veronique, 1995, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V189, P25
  • [7] Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
    Bethel, M. Angelyn
    Patel, Rishi A.
    Merrill, Peter
    Lokhnygina, Yuliya
    Buse, John B.
    Mentz, Robert J.
    Pagidipati, Neha J.
    Chan, Juliana C.
    Gustavson, Stephanie M.
    Iqbal, Nayyar
    Maggioni, Aldo P.
    Ohman, Peter
    Poulter, Neil R.
    Ramachandran, Ambady
    Zinman, Bernard
    Hernandez, Adrian F.
    Holman, Rury R.
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (02) : 105 - 113
  • [8] Obesity: global epidemiology and pathogenesis
    Blueher, Matthias
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2019, 15 (05) : 288 - 298
  • [9] Metformin and Incident Breast Cancer among Diabetic Women: A Population-Based Case-Control Study in Denmark
    Bosco, Jaclyn Lee Fong
    Antonsen, Sussie
    Sorensen, Henrik Toft
    Pedersen, Lars
    Lash, Timothy L.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2011, 20 (01) : 101 - 111
  • [10] Cancer Risk for Patients Using Thiazolidinediones for Type 2 Diabetes: A Meta-Analysis
    Bosetti, Cristina
    Rosato, Valentina
    Buniato, Danilo
    Zambon, Antonella
    La Vecchia, Carlo
    Corrao, Giovanni
    [J]. ONCOLOGIST, 2013, 18 (02) : 148 - 156